Drug Topics Newsletter

To view this email as a web page, click here.

PHARMACISTS' REPORT

Telepharmacy Business Model Allows Satellite Operation and Increased Patient Convenience

Adoption of video conferencing technologies improve dispersal and communication to patients and healthcare professionals alike.

Find drug information quickly without having to search for hours

Access more than 20 drug databases featuring timely, in-depth information on drugs, natural products, interactions and more, with Lexicomp^® Mobile Apps—the leading pharmaceutical resource.

Learn More.

Lack of Insurance and Age Restrictions Among Most Common Barriers to Vaccinations

A new study reveals that immunization registries, communication, and the completion of immunization series can increase pharmacists’ role in the immunization process.'

Getting the most out of clicking through BORING continuing education?

Compounding Pharmacist Seth Depasquale, teaches you sterile compounding through demonstrating all you need to know for compliance and beyond. Sign up by December 31st to save 50% ($100 OFF) with this PRE-launch offer by using STERILE at checkout. Available exclusively through

MyPharmacyEducation.com.

Why Our Family and Friends Ignore Our Expert Advice

At the end of the day, we need to adhere to the same consultation rules that we apply to patients.

Sellers & Buyers: Want More from Your Pharmacy Ownership Transition?

More exclusive buyer and seller resources. More pre-qualified buyers. More regional service representatives. More experience and a track record of more successful transitions?

Get More.

Top 5 Ways to Make Vaccinations Less Frustrating

Flu vaccinations can take up lots of your already-busy schedule, but that doesn’t mean they’re not important.

A transparent, accessible, timely drug price benchmark

Predictive Acquisition Cost (PAC) is a drug pricing standard for the pharmacy industry. Learn how you can ensure fair and balanced reimbursements, control costs, and maintain profitable margins.

Read the eBook.

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.

CONNECT